Search alternatives:
patients decrease » point decrease (Expand Search), treatments decreased (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
stem decrease » step decrease (Expand Search), sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
Showing 1 - 20 results of 8,545 for search '(( b large decrease ) OR ((( _ ((stem decrease) OR (teer decrease)) ) OR ( _ patients decrease ))))', query time: 0.43s Refine Results
  1. 1
    The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability.

    The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    NSC population and proliferation decrease drastically during the second postnatal week of DG development.

    NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

    Published 2025
    Save to List
    Saved in:
  4. 4
    <b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>"

    <b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

    Published 2025
    Save to List
    Saved in:
  5. 5
    <i>Leptospira interrogans</i> strains isolated from patients in Okinawa, Japan, in 2023.

    <i>Leptospira interrogans</i> strains isolated from patients in Okinawa, Japan, in 2023. by Tetsuya Kakita (4922584)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Supplementary Material for: Decreased Quality of Life in patients who desire Body Contouring Surgery after Bariatric Metabolic Surgery: A multicenter longitudinal analysis

    Supplementary Material for: Decreased Quality of Life in patients who desire Body Contouring Surgery after Bariatric Metabolic Surgery: A multicenter longitudinal analysis by Dijkhorst P.J. (20584910)

    Published 2025
    Save to List
    Saved in:
  8. 8
    Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class.

    Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class.

    Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 <sup>a</sup> indicates ≥1.50 SD (17.9) from the mean (32.9), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 <sup>a</sup> indicates ≥1.50 SD (17.9) from the mean (32.9... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.4), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1... by Luke R. Cavanah (19022435)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: